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ABSTRACT 
Familial arteriovenous malformations (AVM) in the brain is a very rare disease.  It is 
defined as its occurrence in two or more relatives (up to third-degree relatives) in a 
family without any associated disorders, such as hereditary hemorrhagic telangiectasia.  
We encountered a Japanese family with brain AVM in which four affected members in 
four successive generations were observed.  One DNA sample extracted from 
leukocytes of the proband and ten DNA samples from clipped finger nails of other 
members were available. A genome-wide linkage analysis was performed on this 
pedigree using Affymetrix GeneCip 10K 2.0 Xba Array and MERLIN software.  We 
obtained sufficient performance of SNP genotyping in the fingernail samples with the 
mean SNP call rate of 92.49%, and identified 18 regions with positive LOD scores.  
Haplotype and linkage analyses with microsatellite markers at these regions confirmed 
three possible disease-responsible regions, i.e., 5p13.2-q14.1, 15q11.2-q13.1 and 
18p11.32-p11.22.  Sequence analysis was conducted for ten selected candidate genes at 
5p13.2-q14.1, such as MAP3K1, DAB2, OCLN, FGF10, ESM1, ITGA1, ITGA2, 
EGFLAM, ERBB2IP, and PIK3R1, but no causative genetic alteration was detected.  
This is the first experience of adoption of fingernail DNA to genome-wide, high-density 
SNP microarray analysis, showing candidate brain AVM susceptible regions.  
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1. Introduction 
Arteriovenous malformation (AVM) in the brain is a disease defined by the presence 
of arteriovenous shunt(s) through a nidus of coiled and tortuous vascular connections 
between feeding arteries and draining veins within the brain parenchyma[1].  This 
vascular malformation is thought to be congenital, and develops before or after birth[2] 
from a residual of the primitive artery-vein connection. Its most common symptom is 
intracranial hemorrhage with an estimated risk of 1.3-3.9% yearly after the diagnosis of 
AVM[3]. Other signs may include intractable seizures, headache and ischemic steal 
syndrome. The prevalence of AVM is estimated to be approximately 0.01% and the 
detection rate ranges between 1.12-1.34 per 100 000 person years[1,2].  Although most 
cases of AVM are sporadic, a total of 53 patients from 25 families have been reported[4].  
Familial brain AVM is defined when it occurs in two or more relatives (up to 
third-degree relative) in a family without associated disorders such as hereditary 
hemorrhagic telangiectasia (HHT), is autosomal dominant multisystemic vascular 
dysplasia[4,5].  It is plausible that familial cases are more frequent and could be 
overlooked because of asymptomatic conditions in other relatives.   
Although several causative genes have been elucidated in some heritable syndromic 
AVM[6-16], molecular genetic studies of familial or sporadic AVM remain scant.  
HHT type 1 (HHT1) and HHT type 2 (HHT2) are known to be caused by mutations in 
ENG at 9q34.11 and ACVRL1 (or ALK1) at 12q13.13, respectively[6,7]. Mutations in 
RASA1 at 5q14.3 cause capillary malformation-arteriovenous malformation 
(CM-AVM)[8-12] characterized by small, round-to-oval, pink-red and multiple CM: 
one-third of CV-AVM patients also has fast-flow lesions such as AVM. Mutations in 
PTEN have been implicated in PTEN hamartoma tumor syndromes including 
Bannayan-Riley-Ruvalcaba syndrome, in which AVM occasionally presents[13]. Three 
genes, KIRIT1 (CCM1)[14] at 7q21.2, MGC4607 (CCM2)[15] at 7p13 and PDCD10 
(CCM3)[16] at 3q26.1, are responsible for cerebral cavernous malformation 
(hamartomatous vascular malformations). On the other hand, regarding familial AVM, 
only two linkage analyses using 6 small families have been published by a research 
group[17,18], showing seven possible disease-responsible regions, i.e., 6q25 with the 
highest LOD score, 3p27, 4q34, 7p21, 13q32-q33, 16p13-q12 and 20q11-q13, but failed 
to identify the causative mutation.  In sporadic brain AVM, microarray study showed 
that the VEGFA, ITGA5, ENG and MMP9 genes that may involve vascular development 
or maintenance, are highly expressed in AVM compared with normal brain 
parenchyma[19-21].  
Here we report results of a genome-wide linkage analysis on an AVM family with 
four affected members in two successive generations.  
2. Materials and Methods 
2.1. Subjects 
A Japanese family consisting of 19 members across four generations included two 
patients with brain AVM, one patient with pulmonary AVM and one patient with both 
brain and pulmonary AVM (Figure 1).  The proband (III-3) first exhibited intractable 
epilepsy at 13 years old and was diagnosed by magnetic resonance imaging (MRI) as 
having a brain AVM of two centimeters in diameter located in the right frontal lobe 
(Figure 2). Chest X-ray at the first visit detected a nodular shadow in the right lower 
lung field, and a diagnoses of pulmonary AVM with a 24% of shunt-rate was made 
following angiogram made (Figure 2). This was resected when the proband was 14 
years old. The proband’s brain AVM was treated by gamma knife surgery when she was 
19 years old, followed by treatment with antiepileptic medication. Her mother (II-3) 
died of intracranial hemorrhage due to brain AVM, and the maternal grandfather (I-1) 
died of a cancer.  Another patient (III-5) had asymptomatic brain AVM, which was 
accidentally diagnosed by MRI.  His father (II-5) had pulmonary AVM instead of brain 
AVM.  These four members were assigned to “affected”, six members (II-6, III-1, III-6, 
III-7, IV-1, and IV-2) without AVM confirmed by MRI were “unaffected”, and the 
remaining three (I-2, II-1, and IV-3) who were not assessed by MRI but had neither past 
history of recurrent epistaxis or gastrointestinal tract bleedings were “unknown”.  
None of the members had any AVM-related diseases, such as HHT. Evaluation of 
cutaneous lesions was conducted by examination of the proband and by detailed 
interview of the other family members by the proband and her sister (III-1), who is 
nurse. A total of 13 members participated in this study under informed consent. All 
experimental procedures for this study were approved by Committee for the Ethical 
Issues on Human Genome and Gene Analysis in Nagasaki University.   
 
2.2. DNA Extraction 
As a blood sample was available only from the proband, clipped fingernail samples 
were obtained from 10 of the other 12 members instead. Genomic DNA was extracted 
from the fingernails using a buffer solution containing urea, DDT and proteinase K, as 
reported previously[22,23].  Briefly, clipped fingernails were once frozen in liquid 
nitrogen and crushed into fine powder using Multi-beads ShockerTM (Yasui Kikai, 
Osaka, Japan).  The nail powder was lysed in a urea-lysis solution (2 M urea; 0.5 % 
SDS; 10 mM Tris-HCl, pH 7.5; 0.1 M EDTA) containing 1 mg/ml proteinase K and 40 
mM DDT at 55 °C overnight.  Nail DNA was extracted with phenol/chloroform, and 
precipitated with ethanol and sodium acetate. Precipitated nail DNA was dissolved 
again in extraction buffer (0.5 % SDS; 10 mM Tris-HCl, pH 7.5; 0.1 M EDTA) 
containing 1 mg/ml proteinase K, and incubated at 55 °C overnight. DNA was purified 
again as above, and was suspended in 30 l of 1x TE buffer. 
 
2.3. SNP Genotyping With Affymetrix 10K 2.0 Array  
Blood DNA (250 ng) was processed according to the standard protocol provided by 
the GeneChip Mapping 10K Xba Assay Kit (Affymetrix, Santa Clara, CA).  Fingernail 
DNA was processed in a similar manner but with the two following modifications to 
adapt to the oligonucleotide microarray system[24].  Prolongation of digestion time 
from 120 minutes as the standard protocol to overnight; and increase of the PCR cycle 
number from 35 to 45 cycles.  Data acquired from the Affymetrix GeneChip Operating 
System were analyzed using the Affymetrix GeneChip Genotyping Analysis Software 
(GTYPE) 4.0 to call genotypes.  
 
2.4. Linkage Analysis With SNP-genotype Data and Haplotype Analysis With 
Microsatellite Markers 
Multipoint LOD scores were calculated using MERLIN software[25], under an 
assumption that AVM in the family is transmitted in an autosomal dominant mode with 
reduced penetrance (p = 0.9) and with the disease allele frequency of 0.001.  At loci 
with a positive LOD score by the GeneChip genotyping, possibly disease-associated 
haplotypes were constructed using SNP calls. 
When SNP information was not informative, microsatellite markers were used for 
genotyping. Microsatellite markers used were referred to the National Center for 
Biotechnology Information (NCBI) database.  One each of primer pairs for the 
markers was labeled with FAM, HEX, or NED (Supplementary table 1), and PCR was 
performed in a 10 l mixture containing 5 ng genomic DNA; 0.25 U ExTaq DNA 
polymerase HS-version (TAKARA Bio Inc., Kyoto, Japan); 200 M dNTP; 0.5 M 
primer; 1x ExTaq buffer on the T1 Thermocycler (Biometra, Goettingen, Germany).  
PCR products were separated on Genetic Analyzer 3130xl (AppliedBiosystems), and 
genotyping was carried out using GeneMapper software (AppliedBiosystems).  At the 
regions where the affected individuals have a disease-associated haplotype, two-point 
LOD score was calculated by MLINK program (included in FASTLINK software 
version 4.0P)[26]. 
 
2.5. Mutation Analysis 
Some genes located within candidate regions identified by the linkage analysis were 
selected for further mutation analysis. A few other genes, albeit outside the regions, 
were also subjected to mutation analysis.  Primer pairs for such genes were designed 
using Primer3-web 0.3.0 (http://frodo.wi.mit.edu/primer3/input.htm), according to their 
genomic sequences retrieved from the University of California, Santa Cruz (UCSC) 
Genome Browser Home (http://genome.cse.ucsc.edu/). PCR was carried out in a 15 l 
reaction mixture containing 5 ng DNA; 0.25 U ExTaq DNA polymerase HS version; 
200 mM dNTP; 0.5 M each primer; 1x ExTaq buffer on the T1 Thermocycler. PCR 
products were subjected to direct sequencing, using BigDye Terminator v3.1 Cycle 
sequencing Kit (AppliedBiosystems) and Genetic Analyzer 3130xl.  
Electropherograms of sequences were aligned with ATGC software (GENETYX Corp., 
Tokyo, Japan) to inspect base alterations. 
 
2.6. Search for Genomic Aberration 
To search for copy number change within the candidate loci identified by linkage 
analysis, we used Affymetrix® Genome-Wide Human SNP Array 5.0 (920,568 probes; 
Affymetrix).  Genomic DNA extracted from white blood cell of proband was 
processed according to manufacture’s protocol. Intensity data from each probes were 
obtained from Affymetrix® Genotyping Console 3.0 as a CEL files.  Unpaired copy 
number analysis of whole genome was carried out using Partek Genomics Suite (Partek, 
MO, USA) and regions with copy number change were determined by Hidden Markov 




3.1. Linkage and Haplotype Analyses 
The mean SNP call rate was 92.49% in 11 fingernail DNA samples, compared to 
98.11% in a blood DNA sample from the proband.  Incorrect SNP calls may result in 
seemingly inconsistent parent-child transmissions, but the call rates obtained are 
actually enough for further studies.  We thus advanced to calculate LOD scores using 
these data.   
The linkage analysis using MERLIN software revealed 18 regions with positive  
LOD scores (>0.00).  Of the 18 regions, 14 with the following conditions were 
excluded: those without any functional full-length RefSeq genes; those in small size (< 
200 kb); and those in which some affected members did not have a common haplotype.  
Consequently, four loci, 5p13.2-q14.1, 15q11.2-q13.1, 18p11.32-p11.22 and 
19q13.33-q13.42, remained as possibly linked regions (Figure 1 and Figure 3).   
We then genotyped with microsatellite markers and calculated two-point LOD scores, 
considering the affected, unaffected, and the unknown family members.  We confirmed 
three of the four candidate loci. They were a 48-Mb region between markers rs1366265 
and rs1373965 at 5p13.2-q14.1, a 6-Mb region between rs850819 and rs818089 at 
15q11.2-q13.1, both giving the maximum two-point LOD score of 1.632 ( = 0), and a 
9-Mb region between rs486633 and rs1942150 at 18p11.32-p11.22 with the maximum 
LOD score of 0.851 ( = 0) (Table 1). As a possibly disease-associated haplotype on 
19q13.33-q13.42 was transmitted to two definitively unaffected individuals (III-6 and 
IV-1), chromosome 19 was ruled out from the candidacy (Table 1, Figure 1). 
 
3.2. Mutation Analysis of Candidate Genes 
Within the 48-Mb region at 5p13.2-q14.1, there are about 200 RefSeq genes. Ten 
(MAP3K1, DAB2, OCLN, FGF10, ESM1, ITGA1, ITGA2, EDFLAM, ERBB2IP, and 
PIK3R1) from these genes were focused and selected as candidates for brain AVM, 
since they concern development or maintenance of vessels, are associated with other 
heritable vascular disorders such as HHT, or are expressed in the brain with 
AVM[19-21] .Mutation analyses in these 10 genes revealed no pathologic mutation in 
the proband, although other affected members were not examined because of 
insufficient amount of their DNA.  Although the genes endoglin isoform 1 precursor 
(ENG), activin A receptor type II like 1 (ALK1) and RAS p21 protein activator 1 
(RASA1) are not located in the candidate region, we investigated whether any of them 
are involved in the etiology of AVM in the family as a partial symptom of HHT or 
AVM-CM. Direct sequencing of these three genes failed to show any causative variants.  
Copy number analysis of proband revealed one increased copy number loci at 12q and 
decreased at 2p, 3q, 4q, 6p, 7q and 22q (data not shown). But all these alterations were 
reported previously as copy number polymorphisms (http://projects.tcag.ca/variation/) 
and out of our candidate loci. In addition, neither deletions nor microdeletions were 




We have reported a family consisting of two affected members with brain AVM, one 
with pulmonary AVM and one with both brain and pulmonary AVM.  The condition in 
this family met the criteria of familial brain AVM and seems to be inherited in an 
autosomal dominant mode.  We tried to assign the location of a putative disease-gene 
by linkage analysis and search for mutations by subsequent candidate gene approach.  
The linkage analysis of the family revealed three candidate regions (5p13.2-q14.1, 
15q11.2-q13.1, and 18p11.32-p11.22) with relatively high LOD scores of 1.632, 1.632 
and 0.851, respectively (Table 1).  However, neither region was conclusive. This 
insufficient mapping may have arisen from the small pedigree size, and/or from 
incomplete ascertainment of affected members, e.g., probable existence of 
asymptomatic affected persons among the “unknown” members.  Indeed, as for a 
candidate locus at 5p13.2-q14.1, the proband’s maternal grandmother (I-2) and son 
(IV-3) had a haplotype common to the three affected members (Figure 1), but they were 
fallen into the “unknown” individuals. If DNA from IV-2 was available and if MRI 
examinations of VI-3 and I-2 were carried out, we would have obtained more definitive 
results. As we performed linkage analysis using high density SNP genotyping, 14 small 
regions not containing RefSeq genes or miRNAs showed a positive LOD score. It is 
possible that an unidentified transcribed RNA in one of these regions could cause 
familial AVM, but these regions are candidate loci with a lower priority than those 
containing known genes. Thus, the three regions have remained at present as the equally 
possible loci for AVM.  The three regions do not overlap with a previously reported 
candidate locus of familial brain AVM, i.e. 6p25[17], and do not contain genes 
responsible for syndromic AVM (heritable disorders involving AVM) or cerebral 
cavernous malformations, such as ENG[6], ALK1[7], RASA1[8-12], and PTEN[13], 
KRIT1[14], MGC407[15], PDCD10[16]. 
We then searched for mutations in 10 genes within 5p13.2-q14.1, among which 
MAP3K1, DAB2 and OCLN encode proteins playing roles in the TGF- signaling 
pathway, and FGF10, ESM1, ITGA1, ITGA2, EGFLAM, ERBB2IP and PIK3R1 were 
those expressed in brain AVM tissues by previous microarray analysis[19-21].  
Nevertheless, no pathologic mutation was found in any of them. Because the presence 
of both brain AVM and pulmonary AVM in this pedigree is reminiscent of Hereditary 
Hemorrhagic Telangiectasia, we analyzed ENG and ALK1 for mutations and genomic 
aberrations, which may cause HHT1 and HHT2 respectively[6,7]. The proband did not 
have any mutations in the coding exons or intron/exon boundaries of either gene, nor 
any genomic aberrations at those loci. We also analyzed RASA1 because this may cause 
CM-AVM, which is characteraized by multiple CM and AVM[8-12]. No causative 
mutation or genomic aberration was detected in the proband. Although other genes, 
such as KRIT1, MGC407 and PDCD10, have been shown to cause slow-flow lesions i.e., 
cerebral cavernous malformation [14-16], they were not investigated in the present 
study, because the clinical manifestations in our family did not meet the criteria for 
these diseases. 
Participation of family members and compliance with guidelines for human genome 
researches are critical to conduct a linkage analysis.  Whole-blood samples cannot 
occasionally be available in some family members because of their far domicile.  In 
such the case, fingernail DNA is useful, since clipped fingernails can be mailed in a 
usual way, and stored long at a room temperature, as indicated previously[22,27].  The 
present study is the first experience to adopt fingernail DNA to genome-wide 
high-density SNP microarray analysis. The performance obtained from fingernail DNA 
was sufficient, showing all SNP call rates of >86%.  According to the manufacture’s 
protocol, samples with a SNP call rate of <85% should further be evaluated before 
including the data in downstream analysis. Incorrect SNP calls may make serious 
problems in linkage analysis.  For instance, SNPs with parent-child transmission 
inconsistency may be omitted, leading to a reduced LOD score.  
In conclusion, we have assigned the familial AVM locus to three alternative regions, 
5p13.2-q13.2, 15q11.2-q13.1 and 18p11.32-p11.22, by a genome-wide, high-density, 
SNP-based linkage analysis with fingernail DNA in an AVM family.  However, 
mutation analyses of some genes in the regions failed to identify any pathological 
changes.   
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Table 1.  Two-point LOD scores for brain AVM at various loci 
---------------------------------------------------------------------------------------------------------------- 
Locus  Recombination fraction () 
 ---------------------------------------------------------------------------------- 
 0.00 0.01 0.02 0.03 0.04 0.05 
---------------------------------------------------------------------------------------------------------------- 
AVM5pl17xAC 0.032 0.030 0.029 0.027 0.026 0.025 
D5S418 0.551 0.535 0.518 0.501 0.484 0.467 
AVMch5p25xAC 1.334 1.301 1.268 1.234 1.201 1.167 
AVM5pr18xGT 0.511 0.491 0.472 0.452 0.433 0.414 
AVMch5c27xGT 1.630 1.597 1.564 1.531 1.497 1.463 
AVM5c18xAC 1.373 1.344 1.314 1.285 1.255 1.225 
D5S407 1.632 1.599 1.566 1.532 1.499 1.465 
D5S647 1.154 1.121 1.089 1.056 1.023 0.991 
AVM5qr19xCA 0.810 0.790 0.769 0.748 0.727 0.706 
---------------------------------------------------------------------------------------------------------------- 
D15S1021 0.171 0.164 0.157 0.150 0.143 0.137 
D15S128 0.876 0.858 0.841 0.823 0.805 0.787 
D15S986 0.812 0.791 0.770 0.749 0.728 0.707 
D15S975 0.400 0.387 0.374 0.361 0.348 0.335 
D15S1002 1.330 1.298 1.266 1.234 1.202 1.170 
D15S1019 1.632 1.599 1.566 1.532 1.499 1.465 
---------------------------------------------------------------------------------------------------------------- 
D18S59 0.199 0.214 0.225 0.234 0.241 0.246 
D18S459 0.142 0.136 0.131 0.125 0.120 0.114 
D18S1132 0.677 0.663 0.650 0.636 0.623 0.609 
D18S452 0.851 0.832 0.813 0.794 0.774 0.755 
D18S471 0.240 0.231 0.222 0.214 0.205 0.197 
---------------------------------------------------------------------------------------------------------------- 
D19S927  -0.302  -0.277   -0.254   -0.234   -0.216   -0.200 
D19S418  -2.655  -2.453   -2.257   -2.078   -1.919   -1.778 













Supplementary table 1.  Primer sequences used in the present study 
Name Item Position Band Forward primer (5’->3’) 
Reverse primer (5’->3’) 
AVM5pl17xAC 17xAC chr5:39266704-39266738 5p13.1 CAGGGTACAGCTGAGAATTGC 
GGACAATCAGTCATTCCATTCA 
AVMch5p25xAC 25xAC chr5:42961358-42961407 5p12 TTCTGGGACCTCTTTACTCA 
ACACGGAGACAACAGAAGAC 
AVM5pr18xGT 18xGT chr5:44815955-44815990 5p12 AAAAGCAACCCACTGTCACC 
TGTCCATTACTTCTGACCCTGA 
AVM5c27xGT 27xGT chr5:53278755-53278808 5q11.2 ATGTGGGATCTCATTGTTGT 
GGGAATTTTCTGCCTTTAAT 
AVM5c18xAC 18xAC chr5:54022345-54022381 5q11.2 CATCCCACATTATAAAATGAGTCAGA 
CATCCACCTCAGCCTAGAGAA 























Figure 1. Results of haplotype analysis at polymorphic loci in four regions, 5q13.2-q14.1, 
15q11.2-q13.1, 18p11.32-p11.22 and 19q13.3-q13.42. Underlined individuals indicate 
those examined by MRI, and DNA was unavailable from individuals without haplotypes. 
Polymorphic alleles are numbered and candidate disease-associated haplotypes are 
shown by dotted boxes. Primer sequences designed for CA repeat amplification are 
available in supplementary table.  
 
Figure 2. Imaging of the brain and pulmonary AVM in the proband. (A) MRI scan and 
MR angiogram of the proband. The AVM is located right frontal lobe measured 2.0 x 1.3 
cm. (B) Pulmonary angiograms of the proband. The pulmonary AVM is located in the 
right lower lobe (rtS8b) with 24% of shunt-rate.  
 
Figure 3. Multipoint LOD scores calculated by MERLIN in four chromosomal regions, 
5q13.2-q14.1, 15q11.2-q13.1, 18p11.32-p11.22 and 19q13.3-q13.42. 
